Well. Damn hate being right. Same drivel of working with FDA , Copaxone generic looks to go all the way till October for the supreme court and then still no FDA approval. They are starting trials with Baxter for their lead product. Guess Baxter saw the problem they are having with Copaxone candidate. And they are dropping an Oncology program.. Waiting till October to revisit any potential increase. Good news is they still have enough cash not to push thru a secondary offering, and if they get approval any time this year they will not do one.